"E&P forecast FY24 Daybue sales of US$346M which is in the upper half of ACAD’s guidance".
I have provided some additional data that may be of use in assessing the upcoming Q4 2024 Daybue revenue that will be reported by Acadia shortly:
*E&P forecast has effectively concluded that Q4 2024 Daybue revenue will be US$94.3M greater than the sum of the past 3 quarters to arrive at the US$346M figure.This figure is just 3.4% above the Q3 2024 revenue of US$91.2M.
*By way of a one year on year comparison Q3 2023 Daybue revenue was US$ 87.1M.
*In order to avoid a revenue guidance miss in a couple of weeks US$88.3M is required to get to the bottom of the Acadia 12 month guidance number of US$340M.
Kens
- Forums
- ASX - By Stock
- NEU
- Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome
NEU
neuren pharmaceuticals limited
Add to My Watchlist
10.5%
!
$13.86

Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-47
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.86 |
Change
1.320(10.5%) |
Mkt cap ! $1.702B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $9.892M | 722.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9 | $13.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.87 | 175 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 758 | 13.690 |
12 | 550 | 13.680 |
6 | 499 | 13.670 |
5 | 1180 | 13.660 |
6 | 1584 | 13.650 |
Price($) | Vol. | No. |
---|---|---|
13.700 | 2 | 1 |
13.710 | 455 | 6 |
13.720 | 446 | 4 |
13.730 | 1200 | 6 |
13.740 | 1380 | 5 |
Last trade - 12.57pm 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online